Chargement en cours...
The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
SIMPLE SUMMARY: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) has shown variable response rates between 9% and 39%. Therefore, better criteria are needed that help doctors to identify patients who will show a favorable outcome to PRRT, and which patients may not. The so...
Enregistré dans:
| Publié dans: | Cancers (Basel) |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7915791/ https://ncbi.nlm.nih.gov/pubmed/33562643 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040635 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|